Cognitive FunctionNCT05652725
Radicle Clarity: A Study of Health and Wellness Products on Mental Clarity and Health Outcomes
A study testing Clarity Active Study Product 1.1 Usage, Clarity Active Study Product 2.1 Usage and Clarity Active Study Product 3.1 Usage in people with Cognitive Function, run by Radicle Science at 1 site in United States.
Trial summary
A randomized, blinded, placebo-controlled direct-to-consumer study of health and wellness products on mental clarity and other health outcomes Read more about this study
- Who is it for?
- Ages 21 to 105 yearsHealthy volunteers can take part
- Conditions the study is for
- Cognitive Function
- What is being tested?
- Clarity Active Study Product 1.1 Usage, Clarity Active Study Product 2.1 Usage and Clarity Active Study Product 3.1 Usage
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 4,826 participants
- Where
- 1 siteUnited States
- Study dates
- 9 Jan 2023to 24 Apr 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 105 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adults, 21 years of age and older at the time of electronic consent, inclusive of all ethnicities, races, genders and/or gender identities
- Resides in the United States
- Endorses better concentration as a primary desire
- Selects concentration and/or looking to improve their concentration as a reason for their interest in taking a health and wellness product
- Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study
Who cannot join
- Reports being pregnant, trying to become pregnant, or breastfeeding
- Unable to provide a valid US shipping address and mobile phone number
- The calculated validated health survey (PRO) score during enrollment represents less than mild impairment or severity
- Reports a diagnosis of liver or kidney disease
- Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)
- Unable to read and understand English
Show all 11Show fewer
- Reports current enrollment in a clinical trial
- Lack of reliable daily access to the internet
- Reports current or recent (within 3 months) use of chemotherapy or immunotherapy
- Reports taking medications with a known moderate or severe interaction with any of the active ingredients studied or a substantial safety risk: Anticoagulants, a medication that warns against grapefruit consumption, corticosteroids at doses greater than 5 mgs per day, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, or MAOIs (monoamine oxidase inhibitors)
- Reports a diagnosis of heart disease when a known contraindication exists for any of the active ingredients studied: NYHA (New York Heart Association) Class III or IV congestive heart failure, Atrial fibrillation, Uncontrolled arrhythmias
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Radicle™ Clarity: A Randomized, Blinded, Placebo-Controlled Direct-to-Consumer Study of Health and Wellness Products on Cognitive Function and Other Health Outcomes
A randomized, blinded, placebo-controlled direct-to-consumer study of health and wellness products on mental clarity and other health outcomes
Read the detailed description
This is a randomized, blinded, placebo-controlled study conducted with adult participants, age 21 and older and residing in the United States.
Eligible participants will (1) endorse a desire for better concentration, (2) indicate an interest in taking a health and wellness product to potentially help their concentration, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study.
Participants with known liver or kidney disease, heavy drinkers, and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Those taking certain medications will be excluded.
Self-reported data are collected electronically from eligible participants over 7 weeks. Participant reports of health indicators will be collected during baseline, throughout the active period of study product use, and in a final survey. All study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study.
- Conditions
- Cognitive Function
- Being tested
- Clarity Active Study Product 1.1 Usage, Clarity Active Study Product 2.1 Usage, Clarity Active Study Product 3.1 Usage, Clarity Active Study Product 4.1 Usage, Clarity Active Study Product 4.2 Usage
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Clarity Active Study Product 1.1 UsageDietary supplement
Participants will use their Radicle Clarity Active Study Product 1.1 as directed for a period of 6 weeks.
Clarity Active Study Product 2.1 UsageDietary supplement
Participants will use their Radicle Clarity Active Study Product 2.1 as directed for a period of 6 weeks.
Clarity Active Study Product 3.1 UsageDietary supplement
Participants will use their Radicle Clarity Active Study Product 3.1 as directed for a period of 6 weeks.
Clarity Active Study Product 4.1 UsageDietary supplement
Participants will use their Radicle Clarity Active Study Product 4.1 as directed for a period of 6 weeks.
Clarity Active Study Product 4.2 UsageDietary supplement
Participants will use their Radicle Clarity Active Study Product 4.2 as directed for a period of 6 weeks.
Clarity Active Study Product 4.3 UsageDietary supplement
Participants will use their Radicle Clarity Active Study Product 4.3 as directed for a period of 6 weeks.
Placebo Control Form 1Dietary supplement
Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
Placebo Control Form 2Dietary supplement
Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
Placebo Control Form 3Dietary supplement
Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
Placebo Control Form 4Dietary supplement
Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.
Placebo Control Form 5Dietary supplement
Participants will use their Placebo Control Form 5 as directed for a period of 6 weeks.
Clarity Active Study Product 5.1 UsageDietary supplement
Participants will use their Radicle Clarity Active Study Product 5.1 as directed for a period of 6 weeks.
Clarity Active Study Product 5.2 UsageDietary supplement
Participants will use their Radicle Clarity Active Study Product 5.2 as directed for a period of 6 weeks.
| Study group | Role | What they receive |
|---|---|---|
| Placebo Control 1 | Placebo comparator | Clarity Product Form 1 - control Receives: Dietary Supplement: Placebo Control Form 1 |
| Placebo Control 2 | Placebo comparator | Clarity Product Form 2 - control Receives: Dietary Supplement: Placebo Control Form 2 |
| Placebo Control 3 | Placebo comparator | Clarity Product Form 3 - control Receives: Dietary Supplement: Placebo Control Form 3 |
| Placebo Control 4 | Placebo comparator | Clarity Product Form 4 - control Receives: Dietary Supplement: Placebo Control Form 4 |
| Active Product 1.1 | Experimental | Clarity Product Form 1 - active product 1 Receives: Dietary Supplement: Clarity Active Study Product 1.1 Usage |
| Active Product 2.1 | Experimental | Clarity Product Form 2 - active product 1 Receives: Dietary Supplement: Clarity Active Study Product 2.1 Usage |
| Active Product 3.1 | Experimental | Clarity Product Form 3 - active product 1 Receives: Dietary Supplement: Clarity Active Study Product 3.1 Usage |
| Active Product 4.1 | Experimental | Clarity Product Form 4 - active product 1 Receives: Dietary Supplement: Clarity Active Study Product 4.1 Usage |
| Active Product 4.2 | Experimental | Clarity Product Form 4 - active product 2 Receives: Dietary Supplement: Clarity Active Study Product 4.2 Usage |
| Active Product 4.3 | Experimental | Clarity Product Form 4 - active product 3 Receives: Dietary Supplement: Clarity Active Study Product 4.3 Usage |
| Placebo Control 5 | Placebo comparator | Clarity Product Form 5 - control Receives: Dietary Supplement: Placebo Control Form 5 |
| Active Product 5.1 | Experimental | Clarity Product Form 5 - active product 1 Receives: Dietary Supplement: Clarity Active Study Product 5.1 Usage |
| Active Product 5.2 | Experimental | Clarity Product Form 5 - active product 2 Receives: Dietary Supplement: Clarity Active Study Product 5.2 Usage |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in cognition (mental clarity)
Mean difference in cognition score as assessed by Patient Reported Outcome Measurement System (PROMIS) Cognitive Function Short Form 8A (scale 8-40; where the higher scores correspond to greater cognitive function)
Measured: 6 weeks
Secondary outcomes (7)
Change in executive functioning
Mean difference in cognition score as assessed by Adult Executive Functioning Inventory (ADEXI) (scale 1-5; with higher scores corresponding to lower executive functioning)
Measured: 6 weeks
Change in sleep quality
Mean difference in sleep quality score as assessed by PROMIS Sleep Disturbance 4A (scale 4-20; with higher scores corresponding to greater sleep disturbance)
Measured: 6 weeks
Change in energy (fatigue)
Mean difference in energy score as assessed by PROMIS Fatigue 4A (scale 4-20; where higher scores correspond to more severe fatigue)
Measured: 6 weeks
Change in anxiety
Mean difference in anxiety score as assessed by PROMIS Anxiety 4A (scale 4-20; with higher scores corresponding to more severe anxiety)
Measured: 6 weeks
Change in mood (emotional distress)
Mean difference in mood score as assessed by PROMIS Depression 4A (scale 4-20; where higher scores correspond to more severe depression)
Measured: 6 weeks
Change in libido
Mean difference in libido score as assessed by PROMIS Sexual Interest 2.0 (scale 2-10; where higher scores correspond to greater sexual interest)
Measured: 6 weeks
Minimal clinical importance difference (MCID) in cognitive function
Likelihood of achieving a MCID in cognitive function, as measured by PROMIS Cognitive Function Short Form 8A (scale 8-40; where the higher scores correspond to greater cognitive function)
Measured: 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Dec 2022
- Study start9 Jan 2023
- Primary completion12 Dec 2023
- Study completion24 Apr 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cognitive FunctionStudies of the same condition, open and under way.
- More trials run by Radicle ScienceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be stratified based on gender at birth then randomized to one of the study arm
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 4,826 participants (actual)
Sponsor and investigators
- Lead sponsor
- Radicle Science
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Emily K. Pauli, PharmD, Principal investigator, Radicle Science Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05652725
- Sponsor's protocol ID
- RADX-2306
- Status last verified
- May 2024
- First submitted
- 7 Dec 2022
- Last updated
- 20 May 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Data will not be shared with researchers outside of Radicle Collaborators on this study.
Study at a glance
From the registry record, last updated by the sponsor on 20 May 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Radicle™ Clarity: A Randomized, Blinded, Placebo-Controlled Direct-to-Consumer Study of Health and Wellness Products on Cognitive Function and Other Health Outcomes
- ClinicalTrials.gov ID
- NCT05652725
- Acronym / sponsor ID
- RADX-2306
- Conditions
- Cognitive Function
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 4,826 participants (actual)
- Lead sponsor
- Radicle ScienceIndustry (pharma, biotech, devices)
- Study start
- 9 Jan 2023 (actual)
- Primary completion
- 12 Dec 2023 (actual)
- Study completion
- 24 Apr 2024 (actual)
- First posted
- 15 Dec 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A randomized, blinded, placebo-controlled direct-to-consumer study of health and wellness products on mental clarity and other health outcomes
Detailed description
This is a randomized, blinded, placebo-controlled study conducted with adult participants, age 21 and older and residing in the United States.
Eligible participants will (1) endorse a desire for better concentration, (2) indicate an interest in taking a health and wellness product to potentially help their concentration, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study.
Participants with known liver or kidney disease, heavy drinkers, and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Those taking certain medications will be excluded.
Self-reported data are collected electronically from eligible participants over 7 weeks. Participant reports of health indicators will be collected during baseline, throughout the active period of study product use, and in a final survey. All study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 13
- Model description
- Participants will be stratified based on gender at birth then randomized to one of the study arm
| Arm | Type | Receives |
|---|---|---|
| Placebo Control 1 | Placebo comparator | Dietary Supplement: Placebo Control Form 1Clarity Product Form 1 - control |
| Placebo Control 2 | Placebo comparator | Dietary Supplement: Placebo Control Form 2Clarity Product Form 2 - control |
| Placebo Control 3 | Placebo comparator | Dietary Supplement: Placebo Control Form 3Clarity Product Form 3 - control |
| Placebo Control 4 | Placebo comparator | Dietary Supplement: Placebo Control Form 4Clarity Product Form 4 - control |
| Active Product 1.1 | Experimental | Dietary Supplement: Clarity Active Study Product 1.1 UsageClarity Product Form 1 - active product 1 |
| Active Product 2.1 | Experimental | Dietary Supplement: Clarity Active Study Product 2.1 UsageClarity Product Form 2 - active product 1 |
| Active Product 3.1 | Experimental | Dietary Supplement: Clarity Active Study Product 3.1 UsageClarity Product Form 3 - active product 1 |
| Active Product 4.1 | Experimental | Dietary Supplement: Clarity Active Study Product 4.1 UsageClarity Product Form 4 - active product 1 |
| Active Product 4.2 | Experimental | Dietary Supplement: Clarity Active Study Product 4.2 UsageClarity Product Form 4 - active product 2 |
| Active Product 4.3 | Experimental | Dietary Supplement: Clarity Active Study Product 4.3 UsageClarity Product Form 4 - active product 3 |
| Placebo Control 5 | Placebo comparator | Dietary Supplement: Placebo Control Form 5Clarity Product Form 5 - control |
| Active Product 5.1 | Experimental | Dietary Supplement: Clarity Active Study Product 5.1 UsageClarity Product Form 5 - active product 1 |
| Active Product 5.2 | Experimental | Dietary Supplement: Clarity Active Study Product 5.2 UsageClarity Product Form 5 - active product 2 |
Who may qualify
- Ages
- 21 to 105 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Adults, 21 years of age and older at the time of electronic consent, inclusive of all ethnicities, races, genders and/or gender identities
- Resides in the United States
- Endorses better concentration as a primary desire
- Selects concentration and/or looking to improve their concentration as a reason for their interest in taking a health and wellness product
- Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study
Key exclusion criteria (11 listed)
- Reports being pregnant, trying to become pregnant, or breastfeeding
- Unable to provide a valid US shipping address and mobile phone number
- The calculated validated health survey (PRO) score during enrollment represents less than mild impairment or severity
- Reports a diagnosis of liver or kidney disease
- Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Clarity Active Study Product 1.1 UsageParticipants will use their Radicle Clarity Active Study Product 1.1 as directed for a period of 6 weeks. | Dietary supplement | Active Product 1.1 |
| Clarity Active Study Product 2.1 UsageParticipants will use their Radicle Clarity Active Study Product 2.1 as directed for a period of 6 weeks. | Dietary supplement | Active Product 2.1 |
| Clarity Active Study Product 3.1 UsageParticipants will use their Radicle Clarity Active Study Product 3.1 as directed for a period of 6 weeks. | Dietary supplement | Active Product 3.1 |
| Clarity Active Study Product 4.1 UsageParticipants will use their Radicle Clarity Active Study Product 4.1 as directed for a period of 6 weeks. | Dietary supplement | Active Product 4.1 |
| Clarity Active Study Product 4.2 UsageParticipants will use their Radicle Clarity Active Study Product 4.2 as directed for a period of 6 weeks. | Dietary supplement | Active Product 4.2 |
| Clarity Active Study Product 4.3 UsageParticipants will use their Radicle Clarity Active Study Product 4.3 as directed for a period of 6 weeks. | Dietary supplement | Active Product 4.3 |
| Placebo Control Form 1Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks. | Dietary supplement | Placebo Control 1 |
| Placebo Control Form 2Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks. | Dietary supplement | Placebo Control 2 |
| Placebo Control Form 3Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks. | Dietary supplement | Placebo Control 3 |
| Placebo Control Form 4Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks. | Dietary supplement | Placebo Control 4 |
| Placebo Control Form 5Participants will use their Placebo Control Form 5 as directed for a period of 6 weeks. | Dietary supplement | Placebo Control 5 |
| Clarity Active Study Product 5.1 UsageParticipants will use their Radicle Clarity Active Study Product 5.1 as directed for a period of 6 weeks. | Dietary supplement | Active Product 5.1 |
| Clarity Active Study Product 5.2 UsageParticipants will use their Radicle Clarity Active Study Product 5.2 as directed for a period of 6 weeks. | Dietary supplement | Active Product 5.2 |
Primary outcome
Change in cognition (mental clarity)
Time frame: 6 weeks
Mean difference in cognition score as assessed by Patient Reported Outcome Measurement System (PROMIS) Cognitive Function Short Form 8A (scale 8-40; where the higher scores correspond to greater cognitive function)
7 secondary outcomes
Change in executive functioning
Time frame: 6 weeks
Change in sleep quality
Time frame: 6 weeks
Change in energy (fatigue)
Time frame: 6 weeks
Change in anxiety
Time frame: 6 weeks
Change in mood (emotional distress)
Time frame: 6 weeks
Change in libido
Time frame: 6 weeks
Minimal clinical importance difference (MCID) in cognitive function
Time frame: 6 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 May 2024.
- Radicle Science, IncLink provided by the sponsor.
- Individual participant dataSharing planned: No. Data will not be shared with researchers outside of Radicle Collaborators on this study.
Related trials for Cognitive Function
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Not yet recruitingPhase 2
Lisdexamfetamine For the Treatment of Conduct Disorder in Children
Conduct Disorder
RecruitingPhase 4
Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery
Head and Neck Cancer (H&N)
Recruiting
HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms
Alzheimer Disease, Dementia
RecruitingObservational study
Locus Coeruleus and CCHS (Congenital Central Hypoventilation Syndrome)
Ondine Syndrome (Congenital Central Hypoventilation Syndrome)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Emily K. Pauli, PharmD principal investigator
Radicle Science Inc.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Clarity Active Study Product 1.1 Usage, Clarity Active Study Product 2.1 Usage and Clarity Active Study Product 3.1 Usage in people with Cognitive Function, run by Radicle Science at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 May 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in cognition (mental clarity) (time frame: 6 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 May 2024.